MicroRNAome expression in chronic lymphocytic leukemia: Comparison with normal B-cell subsets and correlations with prognostic and clinical parameters

Clinical Cancer Research

Volumn 20, Issue 15, 2014, Pages 4141-4153

  Negrini, Massimo ^a,b   Cutrona, Giovanna ^d   Bassi, Cristian ^a   Fabris, Sonia ^e   Zagatti, Barbara ^a   Colombo, Monica ^d   Ferracin, Manuela ^a,b   D'Abundo, Lucilla ^a   Saccenti, Elena ^c   Matis, Serena ^d   Lionetti, Marta ^e   Agnelli, Luca ^e   Gentile, Massimo ^f   Recchia, Anna Grazia ^f   Bossio, Sabrina ^f   Reverberi, Daniele ^d   Rigolin, Gianmatteo ^c   Calin, George A ⁱ   Sabbioni, Silvia ^a   Russo, Giandomenico ^g   Tassone, Pierfrancesco ^h   Morabito, Fortunato ^f   Ferrarini, Manlio ^d   Neri, Antonino ^e   more..

^a UNIVERSITY OF FERRARA   (Italy)

^b Laboratorio per Tecnologie delle Terapie Avanzate   (Italy)

^c UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f Azienda Ospedaliera   (Italy)

^g LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^h UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

ⁱ UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 103; MICRORNA 126; MICRORNA 130A; MICRORNA 146 5P; MICRORNA 148B; MICRORNA 16; MICRORNA 190B; MICRORNA 193B; MICRORNA 196A; MICRORNA 196B; MICRORNA 23B; MICRORNA 26A; MICRORNA 27B; MICRORNA 29C; MICRORNA 32; MICRORNA 330 3P; MICRORNA 33B; MICRORNA 340; MICRORNA 361 5P; MICRORNA 362 5P; MICRORNA 365; MICRORNA 500; MICRORNA 502 3P; MICRORNA 532 3P; MICRORNA 532 5P; MICRORNA 625; MICRORNA 744; PROTEIN KINASE ZAP 70; UNCLASSIFIED DRUG; IMMUNOGLOBULIN HEAVY CHAIN;

ARTICLE; B LYMPHOCYTE; BLOOD; CANCER GROWTH; CANCER PROGNOSIS; CELL SUBPOPULATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; GENE; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IGHV GENE; MAJOR CLINICAL STUDY; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TONSIL; CELL CULTURE; CHROMOSOME ABERRATION; COMPARATIVE STUDY; DISEASE COURSE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN CHROMOSOME; METABOLISM; MUTATION; PATHOLOGY; TRISOMY;

B-LYMPHOCYTE SUBSETS; CELLS, CULTURED; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICRORNAS; MUTATION; TRISOMY;

EID: 84905454021     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2497     Document Type: Article

References (50)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-15.
2. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-6.
3. Gaidano G, Foa R, Dalla-Favera R. Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest 2012;122:3432-8.
4. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005;353:1793-801.
5. Joshi D, Gosh K, Vundinti BR. MicroRNAs in hematological malignancies: a novel approach to targeted therapy. Hematology 2012;17:170-5.
6. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A 2004;101:11755-60.
7. Fulci V, Chiaretti S, Goldoni M, Azzalin G, Carucci N, Tavolaro S, et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 2007;109:4944-51.
8. Lawrie CH, Saunders NJ, Soneji S, Palazzo S, Dunlop HM, Cooper CD, et al. MicroRNA expression in lymphocyte development and malignancy. Leukemia 2008;22:1440-6.
9. Lawrie CH, Ballabio E, Dyar OJ, Jones M, Ventura R, Chi J, et al. MicroRNA expression in chronic lymphocytic leukaemia. Br J Haematol 2009;147:398-402.
10. Li S, Moffett HF, Lu J, Werner L, Zhang H, Ritz J, et al. MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells. PLoS One 2011;6:e16956.
11. Cutrona G, Colombo M, Matis S, Fabbi M, Spriano M, Callea V, et al. Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells. Haematologica 2008;93:413-22.
12. Morabito F, De Filippi R, Laurenti L, Zirlik K, Recchia AG, Gentile M, et al. The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia. Blood 2011;118:6353-61.
13. Zenz T, Mohr J, Eldering E, Kater AP, Buhler A, Kienle D, et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 2009;113:3801-8.
14. Zenz T, Habe S, Denzel T, Mohr J, Winkler D, Buhler A, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009;114:2589-97.
15. Mosca L, Fabris S, Lionetti M, Todoerti K, Agnelli L, Morabito F, et al. Integrative genomics analyses reveal molecularly distinct subgroups of B-cell chronic lymphocytic leukemia patients with 13q14 deletion. Clin Cancer Res 2010;16:5641-53.
16. Dono M, Zupo S, Leanza N, Melioli G, Fogli M, Melagrana A, et al. Heterogeneity of tonsillar subepithelial B lymphocytes, the splenic marginal zone equivalents. J Immunol 2000;164:5596-604.
17. Basso K, Sumazin P, Morozov P, Schneider C, Maute RL, Kitagawa Y, et al. Identification of the human mature B cell miRNome. Immunity 2009;30:744-52.
18. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001;194:1625-38.
19. Seifert M, Sellmann L, Bloehdorn J, Wein F, Stilgenbauer S, Durig J, et al. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med 2012;209:2183-98.
20. Kikushige Y, Ishikawa F, Miyamoto T, Shima T, Urata S, Yoshimoto G, et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 2011;20:246-59.
21. Gross E, Quillet-Mary A, Ysebaert L, Laurent G, Fournie JJ. Cancer stem cells of differentiated B-cell malignancies: models and consequences. Cancers (Basel) 2011;3:1566-79.
22. Chiorazzi N, Ferrarini M. Cellular origin (s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood 2011;117:1781-91.
23. Mraz M, Malinova K, Kotaskova J, Pavlova S, Tichy B, Malcikova J, et al. miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia 2009;23:1159-63.
24. Rigolin GM, Saccenti E, Rizzotto L, Ferracin M, Martinelli S, Formigaro L, et al. Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients. Oncotarget 2014;5:140-9.
25. Ferrajoli A, Shanafelt TD, Ivan C, Shimizu M, Rabe KG, Nouraee N, et al. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood 2013;122:1891-9.
26. Dufour A, Palermo G, Zellmeier E, Mellert G, Duchateau-Nguyen G, Schneider S, et al. Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients. Blood 2013;121:3650-7.
27. Visone R, Veronese A, Rassenti LZ, Balatti V, Pearl DK, Acunzo M, et al. miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood 2011;118:3072-9.
28. Rossi S, Shimizu M, Barbarotto E, Nicoloso MS, Dimitri F, Sampath D, et al. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 2010;116:945-52.
29. Vargova K, Curik N, Burda P, Basova P, Kulvait V, Pospisil V, et al. MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. Blood 2011;117:3816-25.
30. Mraz M, Dolezalova D, Plevova K, Stano Kozubik K, Mayerova V, Cerna K, et al. MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia. Blood 2012;119:2110-3.
31. Bomben R, Gobessi S, Dal Bo M, Volinia S, Marconi D, Tissino E, et al. The miR-17 approximately 92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. Leukemia 2012;26:1584-93.
32. Kovaleva V, Mora R, Park YJ, Plass C, Chiramel AI, Bartenschlager R, et al. miRNA-130a targets ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cells. Cancer Res 2012;72:1763-72.
33. Zhu DX, Fan L, Lu RN, Fang C, Shen WY, Zou ZJ, et al. Downregulated Dicer expression predicts poor prognosis in chronic lymphocytic leukemia. Cancer Sci 2012;103:875-81.
34. Rauhala HE, Jalava SE, Isotalo J, Bracken H, Lehmusvaara S, Tammela TL, et al. miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer 2010;127:1363-72.
35. Zhu W, Shan X, Wang T, Shu Y, Liu P. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010;127:2520-9.
36. Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, et al. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 2011;71:225-33.
37. Narducci MG, Arcelli D, Picchio MC, Lazzeri C, Pagani E, Sampogna F, et al. MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sezary syndrome. Cell Death Dis 2011;2:e151.
38. Forrest AR, Kanamori-Katayama M, Tomaru Y, Lassmann T, Ninomiya N, Takahashi Y, et al. Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation. Leukemia 2010;24:460-6.
39. Sun X, Icli B, Wara AK, Belkin N, He S, Kobzik L, et al. MicroRNA-181b regulates NF-kappaB-mediated vascular inflammation. J Clin Invest 2012;122:1973-90.
40. Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 2006;66:11590-3.
41. Gao XN, Lin J, Gao L, Li YH, Wang LL, Yu L. MicroRNA-193b regulates c-Kit proto-oncogene and represses cell proliferation in acute myeloid leukemia. Leuk Res 2011;35:1226-32.
42. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005;115:755-64.
43. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2010;17:193-9.
44. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E (mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A 2006;103:7024-9.
45. O'Connell RM, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, Nicoll J, et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 2008;205:585-94.
46. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639-47.
47. Stamatopoulos B, Meuleman N, Haibe-Kains B, Saussoy P, Van Den Neste E, Michaux L, et al. microRNA-29c and microRNA-223 downregulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood 2009;113:5237-45.
48. Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W, et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010;115:2630-9.
49. Pekarsky Y, Croce CM. Is miR-29 an oncogene or tumor suppressor in CLL? Oncotarget 2010;1:224-7.
50. Santanam U, Zanesi N, Efanov A, Costinean S, Palamarchuk A, Hagan JP, et al. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci U S A 2010;107:12210-5.